Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in Boston, Massachusetts

This page shows live ClinicalTrials.gov search results for Boston, Massachusetts, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 9:02 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
5282
Shown on this page
12
Current sort
Recently updated
Location scope
Boston, MA
Filters apply within this location only.

The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.

Filter and sort this location

These controls apply only within Boston, Massachusetts. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 349–360 of 5,282 matching trials in Boston, MA.
Indexed local directory records.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Institutions in Boston

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Stored official records

Open in full search
Recruiting Phase 2Phase 3 Interventional

A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)

NCT07058077
View directory record Official record
Conditions
Heterozygous Familial Hypercholesterolemia (HeFH)
Interventions
Enlicitide Decanoate, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
6 Years to 17 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2037
U.S. locations
8
States / cities
Wilmington, Delaware • Washington D.C., District of Columbia • Boca Raton, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 10, 2026, 9:15 AM EST
Recruiting Phase 1Phase 2 Interventional

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

NCT07020221
View directory record Official record
Conditions
Colorectal Cancer, G12D Mutated KRAS, Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Solid Tumor, Adult
Interventions
Carboplatin + Pemetrexed + Pembrolizumab, Cetuximab, Defactinib, Gemcitabine + Nab-paclitaxel, Midazolam, Pembrolizumab, Repaglinide, VS-7375
Drug
Lead sponsor
Verastem, Inc.
Industry
Eligibility
18 Years and older
Enrollment
616 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
13
States / cities
Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 10, 2026, 11:53 AM EST
Recruiting Phase 2 Interventional

RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

NCT07002034
View directory record Official record
Conditions
Adjustment Disorder
Interventions
RE104 for Injection
Drug
Lead sponsor
Reunion Neuroscience Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
33
States / cities
Birmingham, Alabama • Tucson, Arizona • San Diego, California + 28 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 11, 2026, 2:49 AM EST
Recruiting Phase 3 Interventional

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

NCT06966700
View directory record Official record
Conditions
Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms, Triple Negative Breast Neoplasms
Interventions
Capecitabine, Carboplatin, Cyclophosphamide, Doxorubicin, Epirubicin, Olaparib, Paclitaxel, Pembrolizumab, Rescue Medication, Sacituzumab tirumotecan
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
2,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
64
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 10, 2026, 3:24 PM EST
Not yet recruiting Early Phase 1 Interventional

Study to Image Inflammatory Activity of a Fluorescence Imaging Agent in Excised Human Artery Plaques

NCT06957821
View directory record Official record
Conditions
Carotid Artery Diseases, Peripheral Arterial Disease
Interventions
Pegulicianine, Placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 12, 2026, 9:02 AM EST
Recruiting Phase 3 Interventional

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

NCT06952504
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Carboplatin, Cisplatin, Docetaxel, Paclitaxel, Pembrolizumab, Sacituzumab Tirumotecan
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
53
States / cities
Mobile, Alabama • Anchorage, Alaska • Irvine, California + 47 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 10, 2026, 7:27 PM EST
Recruiting Not applicable Interventional

Using Non-invasive Brain Stimulation to Treat Word Finding Difficulty in Chronic Traumatic Brain Injury

NCT06848140
View directory record Official record
Conditions
Acquired Brain Injury, Cognitive Change, Cognitive Symptom, Traumatic Brain Injury, Word Finding Difficulty
Interventions
Active Transcranial direct current stimulation, Sham Transcranial direct current stimulation
Device
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 10, 2026, 9:04 AM EST
Recruiting Phase 2 Interventional

Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL

NCT06806033
View directory record Official record
Conditions
Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma
Interventions
Gemcitabine, Glofitamab, Obinutuzumab, Oxaliplatin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
33
States / cities
Anchorage, Alaska • Clovis, California • Fullerton, California + 29 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 11, 2026, 2:45 AM EST
Recruiting Phase 2 Interventional

Spray Cryotherapy for the Management of Benign Central Airway Stenosis (Cryo-BAS)

NCT06761170
View directory record Official record
Conditions
Stenosis of Trachea
Interventions
Spray cryo therapy, Standard of Care (SOC)
Procedure
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 11, 2026, 7:09 AM EST
Completed Not applicable Interventional

A Pilot Project to Facilitate Dental Care and Reduce Barriers For Youth With Disabilities

NCT06710483
View directory record Official record
Conditions
Intellectual Disability, Variable
Interventions
Pre-Dental Telehealth (PDT)
Behavioral
Lead sponsor
Boston University
Other
Eligibility
12 Years to 18 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 11, 2026, 9:40 AM EST
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1

NCT06694805
View directory record Official record
Conditions
HIV Infections
Interventions
CAB LA + RPV LA, Oral ART
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
12 Years and older
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
39
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 29 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 10, 2026, 12:57 PM EST
Active, not recruiting Phase 3 Interventional

A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56

NCT06668064
View directory record Official record
Conditions
Wet Age Related Macular Degeneration, wAMD
Interventions
Aflibercept (2.0 mg), EYP-1901
Drug
Lead sponsor
EyePoint Pharmaceuticals, Inc.
Industry
Eligibility
50 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
76
States / cities
Phoenix, Arizona • Springdale, Arkansas • Bakersfield, California + 70 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 11, 2026, 2:50 AM EST